PARSIPPANY, N.J., May 16, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Pharma, Inc., has launched an authorized generic version of AMRIX® (Cyclobenzaprine Hydrochloride Extended-Release Capsules) 15 mg and 30 mg, as part of an agreement with Anesta AG, a subsidiary of Cephalon, Inc. AMRIX is approved for use along with rest and physical therapy to help control muscle spasm associated with acute, painful musculoskeletal conditions.
Under the terms of the non-exclusive sales agent agreement, Anesta manufactures and supplies Watson with all dosage strengths of the authorized generic product. Watson markets and distributes the product in the United States on behalf of Anesta and will receive payments based on sales of the product. Other terms of the agreement have not been disclosed.
For the most recent twelve months ending March 31, 2011, AMRIX had sales of approximately $125 million, according to IMS Health data.
About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.
For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.
Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended March 31, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.
AMRIX® is a registered trademark of Cephalon, Inc. CONTACTS: Investors:Patty Eisenhaur(862) 261-8141Media:Charlie Mayr(862) 261-8030
|SOURCE Watson Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved